Skip to main content
Donate

About FAST

Contact

Don’t be shy. We’re not :)

Contacting FAST

Reach out to us any time if you have questions, comments, or concerns!

  • Our Community Engagement Team: Community@cureangelman.org

  • Our Fundraising Team: Fundraising@cureangelman.org

  • Our Science Team: Science@cureangelman.org

  • General Inquiries: info@cureangelman.org

Phone: 630-852-FAST (3278) or Toll Free:(866) 783-0078

Connecting on Social Media

Facebook • Instagram • LinkedIN

Subscribe to Our Newsletter

FAST Angelman Syndrome News

MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy ...

FAST Speaks at the 2025 MENA Congress for Rare Diseases

Expanding the Pre-Clinical Research Landscape for Angelman Syndrome

Oak Hill Bio to continue the development of rugonersen, an investigational ASO previously owned by Roch...

CAN Spotlight: Bike 4 Briar Starts May 27th!

FAST-funded researcher highlights the involvement of UBE3A in different neurodegenerative diseases

Progress for Angelman Syndrome Relies on a Strong NIH and FDA

IONIS REVEAL Phase 3 Clinical Trial Update

Exciting Announcement: Launch of Our New Electronic Journal

Community Update: New Insights into Health and Prevention in Angelman Syndrome

The Economic Burden of Caring for Individuals with Angelman Syndrome

CAN Spotlight: Matthew Gocker continues to support AS Family in Wisconsin!

International Angelman Day 2025: Round-Up

FAST Italy Hosts Its First Scientific Symposium on Angelman Syndrome

FAST Poland Organized the 1st Polish National Angelman Syndrome Conference

Introducing the Angelman Syndrome Global Community Advisory Board (CAB)

A high sensitivity assay of UBE3A ubiquitin ligase activity from Dr. Albert Keung’s Lab

2025 AS Congressional Advocacy Day: Legislative Priorities

FAST announces the launch of two biotech companies to advance investigational gene-targeted therapies f...

February 2025: Advocacy updates and actions to take

MavriX Bio Announces FDA Clearance of IND Application to Initiate First-in-Human Study of Gene Therapy ...

FAST Speaks at the 2025 MENA Congress for Rare Diseases

Expanding the Pre-Clinical Research Landscape for Angelman Syndrome

Oak Hill Bio to continue the development of rugonersen, an investigational ASO previously owned by Roch...

CAN Spotlight: Bike 4 Briar Starts May 27th!

FAST-funded researcher highlights the involvement of UBE3A in different neurodegenerative diseases

Progress for Angelman Syndrome Relies on a Strong NIH and FDA

IONIS REVEAL Phase 3 Clinical Trial Update

Exciting Announcement: Launch of Our New Electronic Journal

Community Update: New Insights into Health and Prevention in Angelman Syndrome

The Economic Burden of Caring for Individuals with Angelman Syndrome

CAN Spotlight: Matthew Gocker continues to support AS Family in Wisconsin!

International Angelman Day 2025: Round-Up

FAST Italy Hosts Its First Scientific Symposium on Angelman Syndrome

FAST Poland Organized the 1st Polish National Angelman Syndrome Conference

Introducing the Angelman Syndrome Global Community Advisory Board (CAB)

A high sensitivity assay of UBE3A ubiquitin ligase activity from Dr. Albert Keung’s Lab

2025 AS Congressional Advocacy Day: Legislative Priorities

FAST announces the launch of two biotech companies to advance investigational gene-targeted therapies f...

February 2025: Advocacy updates and actions to take

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.